Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat and Belinostat in Relapsed/Refractory AML or MDS
NCT03772925Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pevonedistat and belinostat in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Primary endpoint: Recommended Phase 2 Dose at 21 days. Started Jun 2019; status: terminated.
02
Drugs
pevonedistatbelinostat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03772925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772925.